Reslizumab (Cinqair)

Covered: Reslizumab (Cinqair) IV 3 mg/kg every 4 weeks as add‑on maintenance for adults ≥18 with severe eosinophilic asthma (blood eosinophils ≥400 cells/µL); not covered for patients <18 or those who do not meet the eosinophil, prior‑therapy, or uncontrolled‑asthma criteria. Key requirements: initial approval (6 months) and renewal (12 months) require documentation of eosinophil count, ≥3 consecutive months of specified controller therapy (ICS + anti‑IL‑5 OR ICS + another controller OR combination ICS/LABA), objective evidence of uncontrolled asthma (≥2 steroid‑treated exacerbations or ≥1 hospitalization/ED visit in past year, FEV1 <80% predicted, FEV1/FVC <0.80, or worsening on OCS taper), prescribing by/consult with an allergist/immunologist/pulmonologist, and for reauthorization ≥6 months on Cinqair with demonstrated clinical response.

"Cinqair is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype."